By PPN News Staff
The FDA revised the emergency use authorization (EUA) for tixagevimab-cilgavimab (Evusheld, AstraZeneca) to allow a higher dose for preexposure prophylaxis (PrEP) of COVID-19 in adults and children who are immunocompromised or cannot receive COVID-19 vaccination for medical reasons.
Based on the most recent information and data available, the original dose of tixagevimab-cilgavimab (150 mg each) may be less active against certain omicron subvariants, the FDA said. However,